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PU.1 is an Ets family transcription factor that is essential for fetal liver hematopoiesis. We 
have generated a 
 
PU.1
 
gfp 
 
reporter strain that allowed us to examine the expression of PU.1 
in all hematopoietic cell lineages and their early progenitors. Within the bone marrow 
progenitor compartment, PU.1 is highly expressed in the hematopoietic stem cell, the 
common lymphoid progenitor, and a proportion of common myeloid progenitors (CMPs). 
Based on Flt3 and PU.1 expression, the CMP could be divided into three subpopulations, 
Flt3
 
  
 
PU.1
 
hi
 
, Flt3
 
  
 
PU.1
 
hi
 
, and Flt3
 
  
 
PU.1
 
lo 
 
CMPs. Colony-forming assays and in vivo lineage 
reconstitution demonstrated that the Flt3
 
  
 
PU.1
 
hi 
 
and Flt3
 
  
 
PU.1
 
hi 
 
CMPs were efficient 
precursors for granulocyte/macrophage progenitors (GMPs), whereas the Flt3
 
  
 
PU.1
 
lo 
 
CMPs 
were highly enriched for committed megakaryocyte/erythrocyte progenitors (MEPs). CMPs 
have been shown to rapidly differentiate into GMPs and MEPs in vitro. Interestingly, short-
term culture revealed that the Flt3
 
  
 
PU.1
 
hi 
 
and Flt3
 
  
 
PU.1
 
hi 
 
CMPs rapidly became CD16/
32
 
high 
 
(reminiscent of GMPs) in culture, whereas the Flt3
 
  
 
PU.1
 
lo 
 
CMPs were the immediate 
precursors of the MEP. Thus, down-regulation of PU.1 expression in the CMP is the first 
molecularly identified event associated with the restriction of differentiation to erythroid 
and megakaryocyte lineages.
 
Hematopoiesis is a continuous stepwise and
controlled process in which the multipotent he-
matopoietic stem cell (HSC) undergoes differen-
tiation to produce all the mature blood lineages.
It has been postulated that the HSC differenti-
ates to either a clonogenic common lymphoid
progenitor (CLP) that produces lymphocytes
and DCs (1) or a common myeloid progenitor
(CMP) capable of giving rise to the erythro-
myeloid lineages. The CMP can further differ-
entiate into either one of two more restricted
progenitors, the granulocyte/macrophage pro-
genitor (GMP) or the megakaryocyte/erythro-
cyte progenitor (MEP; reference 2).
The expression of a number of transcription
factors is thought to orchestrate hematopoietic
differentiation (for review see references 3 and
4). One of these key regulators is PU.1, a
hematopoietic-specific Ets family member that
is essential for fetal lymphoid and myeloid de-
velopment (5–8). 
 
PU.1
 
 
 
/
 
  
 
mice die in late
gestation and are devoid of fetal liver B lym-
phocytes, granulocytes, and macrophages. In
adult hematopoiesis, recent data has suggested
that PU.1 is an important tumor suppressor
in murine and possibly human acute myeloid
leukemia (AML; references 9–11). PU.1 regu-
lates numerous genes within the myeloid and
lymphoid lineages, including the receptors for
a number of cytokines, M-CSFR, G-CSFR,
GM-CSFR
 
  
 
(12), and IL-7R
 
  
 
(13), highlight-
ing the pivotal role this transcription factor plays
in the early stages of several lineages.
It has been proposed that graded levels of
PU.1 expression by hematopoietic progenitors
are determinative of their lineage commitment
as high PU.1 directs macrophage differentiation
and lower levels are sufficient for fetal B cell
development (14, 15), whereas in a more recent
study, intermediate levels of PU.1 were required
for granulocytes (16). However, the relevance
of these results to endogenous PU.1 levels has
not been demonstrated as these studies relied
on overexpression systems. Further support for
the concentration dependence model comes
from the finding that 
 
PU.1
 
 is haploinsufficient
when the mutation is compounded with the
loss of 
 
G-CSF
 
 (16). Moreover, mice with a
hypomorphic 
 
PU.1
 
 allele that express only
20% of wild-type protein develop AML at a
high frequency, a malignancy thought to derive
from primitive hematopoietic cells (9).
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These studies predict that the levels of PU.1 will be dif-
ferentially regulated within the distinct BM multipotent pro-
genitors; however, in no case has the level of PU.1 expres-
sion in myeloid and lymphoid lineage precursor populations
been clearly shown. In this study, we have generated a
 
PU.1
 
gfp 
 
reporter allele that enabled us to accurately determine
the level and pattern of PU.1 expression at the single cell
level. Using these mice, we have examined the rare BM he-
matopoietic progenitor populations and found that PU.1 is
expressed by all HSC, CLP, GMP, Flt3
 
  
 
CMP, and by a pro-
portion of Flt3
 
  
 
CMP. In contrast to expectations, the PU.1
levels in HSC and CLP were equivalent to those observed in
the committed myeloid progenitors. The different levels of
PU.1 expression within the Flt3
 
  
 
CMP population repre-
sented two functionally distinct precursor populations as as-
sessed by in vitro colony-forming assays and in vivo lineage
reconstitution. Therefore, the down-regulation of PU.1 in
Flt3
 
  
 
CMP demonstrates the heterogeneity in this population
and represents an early event in the restriction of the CMP to
erythroid and megakaryocyte (Meg) differentiation.
 
RESULTS
Generation and validation of PU.1
 
gfp 
 
reporter mice
 
To produce a reporter of PU.1 expression, an internal ribo-
some entry site (IRES)-GFP cassette was inserted by homolo-
gous recombination in embryonic stem (ES) cells into the 3
 
 
 
untranslated region of mouse 
 
PU.1
 
 (Fig. 1 A). The detailed
strategy and confirmation of appropriate gene targeting will be
reported elsewhere (unpublished data). The targeted allele re-
sulted in the transcription of a bicistronic mRNA that pro-
duced wild-type PU.1 protein and GFP. The targeting strategy
predicted that the IRES-GFP cassette would not affect the up-
Figure 1. Generation and validation of a PU.1gfp reporter strain. 
(A) The targeted PU.1gfp locus is shown with the exons indicated as boxes 
and the introns as black lines. Coding regions are in gray and nontranslated 
regions are white. Arrows indicate direction of translation from initial 
methionine. pA, polyadenylation signal sequence; circles, frt sites; triangles, 
loxP sites; stop, stop codon; splice acc., splice acceptor. The targeted allele 
translates full-length PU.1 and GFP from the same mRNA transcript. (B) 
GFP expression in PU.1gfp/  BM. Cells were stained for CD19 (B cells) and 
Mac-1 (myeloid cells). (C) GFP expression in B cells and macrophage/
granulocytes of adult spleen of  / , PU.1gfp/ , and PU.1gfp/gfp mice. (D) Quan-
titation of mean fluorescence of B cells (CD19  B220 ), granulocytes 
(Mac-1  Gr.1high), and immature myeloid cells (Mac-1  Gr-1–intermediate 
[Gr.1int]) from BM and spleen. n   4–10 mice per group. Relative mean 
fluorescence was determined relative to identically gated C57BL/6 cells 
and is shown in arbitrary units. (E) Western blotting for PU.1 in BM Mac-1 /
Gr.1  myeloid cells (BMM), CD19  B220  spleen B cells, and CD4  T lym-
phocytes.   actin was a loading control. (F) Determination of PU.1 and GFP 
stability in splenocytes. Cells were cultured for up to 12 h in the protein syn-
thesis inhibitor cyclohexamide, and equivalent cell numbers were assayed 
for PU.1, GFP, and   actin levels by Western blotting. The calculated half-
life of the proteins is indicated (left). 
JEM VOL. 201, January 17, 2005
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stream 
 
PU.1
 
 mRNA transcript. To confirm this, homozygous
 
PU.1
 
gfp/gfp 
 
mice were generated. In contrast to the embryonic
or postnatal lethality of 
 
PU.1
 
 
 
/
 
  
 
pups (5, 6), 
 
PU.1
 
gfp/gfp 
 
mice
were indistinguishable in survival, hematopoietic cellularity,
and lineage composition from C57BL/6 controls (unpublished
data). As predicted, PU.1 protein level in B lymphocytes and
myeloid cells was not affected by the host genotype (Fig. 1 E).
 
PU.1
 
gfp 
 
expression by mature hematopoietic lineage cells
 
PU.1 expression by mature myeloid and lymphoid lineage
cells has been previously examined at mRNA and/or pro-
tein levels (14, 17). However, the results obtained from these
studies could not distinguish whether all, or only a propor-
tion, of cells within a given population express 
 
PU.1
 
. The
 
PU.1
 
gfp 
 
reporter mice provided an excellent tool to clarify
this issue. We examined the GFP fluorescence of different
hematopoietic cell populations from BM and spleen as de-
fined by flow cytometry. The levels of 
 
PU.1
 
 expression were
quantified as the mean fluorescence of GFP expression by
these cells. PU.1 is expressed at significantly higher levels in
macrophages as compared with B cells (14). Analysis of the
lymphoid organs of adult 
 
PU.1
 
gfp/
 
  
 
mice confirmed these lin-
eage-specific expression levels with approximately eightfold
higher GFP observed in all Mac-1
 
  
 
myeloid cells compared
with CD19
 
  
 
B cells (Fig. 1, B and C). The Mac-1
 
  
 
fraction
contains immature granulocytes/monocytes (Gr-1
 
int
 
) and
mature granulocytes (Gr-1
 
hi
 
), all of which displayed similar
GFP fluorescence, indicating relatively uniform 
 
PU.1
 
 tran-
scription throughout granulocytic/monocytic differentia-
tion (Fig. 1, C and D). A similar uniformity was observed for
B lineage cells (Fig. 1, C and D). Analysis of B cell and mac-
rophage/granulocyte populations revealed an exquisite gene
dosage sensitivity of the reporter allele, with 
 
PU.1
 
gfp/gfp 
 
cells
containing almost exactly twice the GFP fluorescence of
heterozygous cells (Fig. 1, C and D). Moreover, determina-
tion of the half-life of the proteins revealed relatively similar
turnover rates (5.5 h for PU.1 and 7.5 h for GFP), indicating
that GFP loss is also an accurate reporter for PU.1 down-
regulation (Fig. 1 F). The lineage-specific and gene dosage–
sensitive levels of GFP in the 
 
PU.1
 
gfp 
 
mice validate the allele
as an accurate reporter of endogenous transcription and en-
abled full characterization of PU.1 expression in a number of
cell types that have not been fully characterized, including
DCs, NK cells, and erythrocyte lineages.
The role of PU.1 in DC development is not clear. PU.1
has been reported to be required for the differentiation of all
DCs (18) or more specifically, for myeloid-derived DCs
(19), with no data available for plasmacytoid DCs (pDCs).
We examined the PU.1
 
gfp 
 
expression by freshly isolated thy-
mic and splenic CD11c
 
  
 
CD45RA
 
  
 
conventional DCs
(cDCs) and the type I IFN–producing CD11c
 
int 
 
CD45RA
 
 
 
pDCs. As shown in Fig. 2, A and B, all of the cDCs from the
thymus and spleen expressed levels of GFP comparable to
myeloid cells. In contrast, all of the pDCs displayed moder-
ate levels of GFP similar to B cells (Fig. 2, A–C). As both
CMPs and CLPs can produce all DC types in vivo, these
data indicate that 
 
PU.1
 
 expression in cDCs is unrelated to
their developmental origin (20).
Figure 2. PU.1gfp expression in DCs and NK cells. (A) The thymic and 
(B) splenic cDCs and pDCs were prepared from the PU.1gfp/gfp mice. The GFP 
fluorescent intensities of cDCs and pDCs were analyzed on gated cDC 
(CD11chi CD45RA ) and pDC (CD11cint CD45RA ) populations and presented 
as histograms. (C) PU.1 expression by cDCs and pDCs were quantified as 
the mean fluorescence of GFP. (D) PU.1gfp expression in mature NK cells 
isolated from BM (CD122  DX5  NK1.1 ). NK cells were also generated 
from BM cultures in the presence of IL-15 for 7 d and assessed for GFP. 
The solid lines represent the PU.1gfp levels and the dotted lines represent 
the background from wild-type mice. 
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It was also reported by an earlier study that NK cells ex-
press 
 
PU.1
 
 mRNA (21). However, we have not observed
any GFP fluorescence in mature NK cells either freshly iso-
lated from mouse BM (CD122
 
  
 
DX5
 
  
 
NK1.1
 
 
 
) or obtained
in culture with IL-15 (Fig. 2 D). 
 
PU.1
 
 might be expressed in
pro–NK cells (CD122
 
  
 
DX5
 
  
 
NK1.1
 
 
 
) and down-regulated
upon maturation; however, a definitive analysis has not been
possible as we have not been able to exclude PU.1-express-
ing myeloid cells from this population (unpublished data).
PU.1 was originally isolated from a virally induced eryth-
roleukemia (22) and is expressed in developing erythroid
progenitors from fetal liver (7, 23). In contrast, adult BM
erythrocytes, neither mature (Ter-119
 
  
 
CD71
 
 
 
) nor imma-
ture (Ter-119
 
  
 
CD71
 
 
 
), showed expression of GFP, indi-
cating that PU.1 is silenced at an early stage of erythropoiesis
(unpublished data).
In summary, the 
 
PU.1
 
gfp 
 
allele described here has allowed
the rapid and quantitative determination of 
 
PU.1
 
 expression
levels in a variety of hematopoietic lineages and revealed a
complex and dynamic expression pattern throughout adult
hematopoiesis.
 
PU.1
 
gfp 
 
expression during thymocyte development
 
Analysis of the PU.1
 
gfp 
 
during T lineage cell development re-
vealed that the majority of thymocytes, including CD4
 
 8 ,
CD4 8 , and CD4 8  were GFP  (Fig. 3 A). In contrast, a
small fraction of the CD4 8  thymocytes was GFP , sug-
gesting that the T cell precursors express PU.1. The earliest
intrathymic precursor population (CD4lo  precursors) dis-
played intermediate levels of GFP, whereas the majority of
the CD3 4 8   CD25   CD117   (triple negative [TN]1)
pro–T cells expressed GFP at a slightly lower level than that
of the CD4lo precursors (Fig. 3, B–D). GFP expression was
maintained in the CD25  CD117  (TN2) precursors before
being markedly down-regulated at the CD25  CD117 
(TN3) stage, coinciding with the onset of TCR gene rear-
rangement (Fig. 3, C and D). These results were consistent
with a previous study in which the PU.1 mRNA expression
by these T cell precursor populations was examined (24).
This loss of PU.1 was permanent as mature peripheral T cells
were GFP  (Fig. 1 E).
PU.1gfp expression by BM hematopoietic 
progenitor populations
The graded levels of PU.1 reported here and observed by
others, has led to a model whereby distinct PU.1 levels arise
in multipotent progenitors and are deterministic of lineage
choice (25). Some of these studies have shown that PU.1
mRNA was expressed at different levels by different he-
matopoietic progenitor populations (2, 26). These data are
problematic because of technical limitations of amplifying
PU.1 from these rare populations. These assays did not indi-
cate if the protein levels were of functional significance, and
finally, they are not able to distinguish whether all of the
cells or only a subset of the cells within a given population
expressed PU.1. The PU.1gfp reporter mice enabled us to ex-
amine the PU.1 expression by different rare hematopoietic
progenitors at the single cell level.
Mouse BM hematopoietic progenitor populations were
isolated as described previously (20). The enriched BM
HSCs were defined as Lin  c-kit  Sca-1  cells and were uni-
formly PU.1gfp high (PU.1hi; Fig. 4 A), suggesting a role of
PU.1 in the earliest stage of hematopoiesis. Interestingly, al-
though the mature B lymphoid cells were low for PU.1gfp,
almost all of the CLPs were PU.1hi (Fig. 4, A and C). The
PU.1 decrease appeared to correlate with B lineage commit-
Figure 3. PU.1gfp expression during T cell development. (A) Total thy-
mocytes from PU.1gfp/gfp mice were analyzed for CD4, CD8, and GFP. The 
PU.1gfp expression by each major thymocyte populations was analyzed on 
gated cells and is presented as histograms. (B) PU.1gfp expression by the 
earliest intrathymic precursor population (CD4lo, CD3 8  Thy-1lo CD117 ). 
(C) CD3 4 8  (TN) thymic precursor populations were isolated and PU.1gfp 
expression by each TN precursor population was analyzed on gated cells. 
(D) The level of PU.1 expression was quantified as the mean fluorescence 
of GFP by each thymic precursor population. The solid lines represent the 
PU.1gfp and the dotted lines represent the background of each cell popula-
tion in     mice.JEM VOL. 201, January 17, 2005 225
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ment as pre-pro–B cells (defined as CD19  B220  CD43 
c-kit ) had already decreased the PU.1gfp expression to a level
comparable with mature B cells (Fig. 4, B and C).
We previously reported that the CMP population could
be divided into two fractions based on the surface Flt3 ex-
pression (20). As shown in Fig. 4 A, all of the Flt3  CMPs
were PU.1hi, but the Flt3  CMPs could be further divided
into two fractions based on differing GFP expression. Ap-
proximately 30–40% of Flt3  CMPs expressed high levels of
PU.1gfp compared with the Flt3  CMPs, whereas the re-
maining Flt3  CMPs ( 60–70%) were PU.1gfp low (PU.1lo;
Fig. 4, A and C). The correlation between PU.1 and GFP
expression was further confirmed using RT-PCR (Fig. 5
C). Therefore, the CMP, originally described as a homoge-
nous clonogenic population, contains at least three subsets,
i.e., Flt3  PU.1hi, Flt3  PU.1hi, and Flt3  PU.1lo. Of the
more downstream committed progenitors, the GMP con-
tained the strongest PU.1gfp fluorescence of any population,
whereas the committed MEP expressed the lowest (Fig. 4,
A and C).
Down-regulation of PU.1 expression is associated with the 
restriction of CMPs to erythroid and Meg differentiation
The majority of CMPs ( 90%) had the morphology of large
undifferentiated blast cells (Fig. 5 A, a and b) and exhibited
mitotic figures. GMPs were generally similar in size but fre-
quently contained small numbers of large granules in the cy-
toplasm resembling those of promyelocytes (Fig. 5 A, c and
d). In contrast, MEPs often had dark cytoplasm and some of
these cells resembled early erythroblasts (Fig. 5 A, e and f).
The fractionated CMP populations had a generally similar
morphology to one another except that some CMP Flt3 
PU.1hi cells had some cytoplasmic granules and some CMP
Flt3  PU.1lo cells had dark cytoplasm (Fig. 5 B).
Figure 4. PU.1gfp expression by BM HSCs and multipotent progenitors. 
(A and B) The BM HSCs and indicated hematopoietic progenitor popula-
tions from PU.1gfp/gfp and wild-type mice were isolated as described in 
Materials and methods. The GFP fluorescence intensity of each progenitor 
population is presented as histograms. The solid lines are from PU.1gfp/gfp 
cells and the dotted lines from  /  mice. (C) Quantitation of the mean 
fluorescence of GFP expression by each cell population.
Table I. Colony-forming potential of the CMP subpopulations
CMP Mean number of coloniesa
Fractions Stimulus Blast G GM M Megb E
SCF 3.0   1.6 7.5   1.9 1.2   0.6 1.2   0.8 0 0
Flt3  IL-3 4.7   0.9 6.0   1.4 9.0   2.9 24.3   8.3 0 0
PU.1hi SCF IL-3 EPO 6.0   2.8 11.0   1.6 13.3   4.2 16.3   6.2 0 0
SCF 2.6   1.2 30.3   11.3 0.3   0.5 0.3   0.5 0 0
Flt3  IL-3 3.3   1.2 29.7   6.1 11.7   4.1 18.0   4.9 2.3   0.6 0
PU.1hi SCF IL-3 EPO 4.3   1.9 29.0   10.0 13.0   2.2 14.0   3.3 5.7   3.7 0.3   0.6
SCF 0.3   0.5 0.4   0.4 0 0.4   0.1 0 0
Flt3  IL-3 1.3   0.8 0.3   0.4 0.2   0.2 0.2   0.2 3.7   0.8 0
PU.1lo SCF IL-3 EPO 1.3   0.9 1.5   0.7 0.3   0.5 1.0   1.4 30.9   3.5 4.0   3.0
100 purified cells of each fraction were cultured for 7 d in 0.3% agar with the growth factors indicated.
aThe numbers of colonies are the mean number of colonies   SD from three separate experiments.
b15–27% of these Meg colonies also contained erythroid cells.
Blast, blast cell colony; G, granulocytic colony; GM granulocyte-macrophage colony; M, macrophage colony; Meg, megakaryocytic colony; E, erythroid colony.REGULATION OF PU.1 LEVELS DURING HEMATOPOIESIS | Nutt et al. 226
To examine the correlation of different levels of Flt3/
PU.1 and cell differentiation potential, in vitro colony-
forming assays were performed (Table I). In the presence of
stem cell factor (SCF), which stimulates the formation of
blast and granulocytic colonies, the Flt3  PU.1hi and Flt3 
PU.1hi CMPs formed small numbers of blast colonies and a
significant number of granulocytic colonies. In contrast,
few Flt3  PU.1lo CMPs exhibited blast or granulocytic col-
ony-forming potential. Similarly, in the presence of IL-3,
which stimulates the colony formation of all cell types,
both Flt3  PU.1hi and Flt3  PU.1hi CMPs formed signif-
icant numbers of granulocytic, granulocyte-macrophage,
and macrophage colonies, whereas the Flt3  PU.1lo CMPs
lacked this potential. Interestingly, the Flt3  PU.1hi CMPs
expressed slightly higher levels of GFP and were more effi-
cient in generating granulocytic colonies than the Flt3 
PU.1hi CMPs (Table I).
Most importantly, when a combination of SCF, IL-3,
and erythropoietin, the most potent stimulus for Meg colony
formation, was used, the Flt3   PU.1hi  and Flt3   PU.1hi
CMPs virtually lacked clonogenic Meg progenitors, whereas,
strikingly,  30% of the Flt3  PU.1lo CMP cells formed Meg
colonies, from 15–27% of which also contained erythroid
Figure 5. Morphology and differential gene expression by the BM 
progenitor populations. (A) Morphology of unseparated CMP (a and b), 
GMP (c and d), and MEP (e and f) populations. (B) Morphology of the indi-
cated three CMP subpopulations. BM progenitor populations were purified 
by flow cytometric cell sorting and cytocentrifuged onto a glass slide and 
stained with May-Grunwald-Giemsa solution. (C) RT-PCR for the expression 
of the indicated genes was performed with the cDNA prepared from each 
progenitor populations. hprt was used as a control for cDNA input.
Figure 6. In vitro differentiation of the CMP subpopulations. The 
three CMP populations, defined as CD16/32int Flt3 , CD16/32int Flt3  
PU.1hi, and CD16/32int Flt3  PU.1lo, were sorted using the gates shown in A 
and cultured on S17 stromal cells in the presence of SCF for 40 h. The levels 
of the PU.1gfp, CD16/32, and Flt3 on freshly isolated precursor populations 
are shown. Flt3  CMP (B), Flt3  PU.1hi CMP (C), and Flt3  PU.1lo CMP (D) 
are shown in the left panels. The phenotypes of the progeny of each pre-
cursor population after 40 h in culture are shown in the right panels. The 
results shown are representative of three experiments.JEM VOL. 201, January 17, 2005 227
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cells. In addition, cells of this type formed small numbers of
pure erythroid colonies (Table I). Thus, the Flt3  PU.1lo
CMPs showed the lowest capacity to form myeloid lineage
colonies, but the highest capacity for megakaryo-erythro-
poiesis. These results demonstrate that the down-regulation
of PU.1 expression is closely associated with loss of myeloid
lineage potential and restriction to Meg and erythroid (MegE)
differentiation.
In support of these clonogenic assays, sorted Flt3  PU.1hi
and Flt3  PU.1hi CMPs and GMPs expressed the mRNA for
m-csfr and g-csfr, whereas the Flt3  PU.1lo CMPs lacked these
transcripts and in contrast expressed low levels of the MegE
regulator gata-1 (Fig. 5 C). This gene expression profile sug-
gests that the Flt3  PU.1lo CMP exhibits the initial activation
of the MegE differentiation pathway.
We have also performed in vivo cell transfer and lineage
reconstitution assays with these sorted populations. Purified
progenitor populations from PU.1gfp/gfp (Ly5.2 ) mice were
intravenously injected together with 5   104 recipient-type
BM cells into lethally irradiated Ly5.1  recipient mice. The
potential of these cells to generate myeloid cells and DCs was
analyzed at 10 and 14 d after transfer. Both the Flt3  PU.1hi
and Flt3  PU.1hi CMPs were able to efficiently produce the
Mac-1  Gr-1  myeloid cells and CD11c  DCs in vivo, with
the Flt3  PU.1hi CMPs being slightly more efficient in gener-
ating these cells (Table II). In comparison, the Flt3  PU.1lo
CMPs gave rise to only a small number of myeloid cells and
very few DCs. These results were consistent with that of col-
ony-forming assays and again demonstrated that the Flt3 
PU.1lo CMPs had the lowest potential to generate myeloid
lineage cells. The CMP has previously been shown to rapidly
differentiate into GMPs and MEPs upon in vitro culture
(2). In an attempt to reveal the developmental relationship
amongst the three CMP populations, an identical short-term
culture system was used. Purified Flt3  PU.1hi, Flt3  PU.1hi,
or Flt3  PU.1lo CMPs were cultured on S17 stromal cells in
the presence of SCF (Fig. 6). After 40 h, the cultured cells
were analyzed for CD16/32, Flt3, and c-kit expression. The
majority of the Flt3  PU.1hi cells had developed into CD16/
32hi Flt3-PU.1hi, a phenotype of GMP (Fig. 6 B). Similarly,
the Flt3  PU.1hi cells also developed into CD16/32hi Flt3-
PU.1hi GMP (Fig. 6 C). In contrast, most of the Flt3  PU.1lo
cells developed into CD16/32 /lo Flt3  PU.1lo, a phenotype
of MEP (Fig. 6 D). Therefore, based on the levels of Flt3 and
PU.1, the originally defined “CMP” population contains
three separate populations that did not display any precursor–
product relationship. Moreover, the combination of three ap-
proaches to determine the developmental potential of these
newly identified CMP fractions demonstrated that PU.1
down-regulation is a very early event in the divergence of the
myeloid and MegE lineages.
DISCUSSION
One model of hematopoietic lineage commitment proposes
that the relative levels of key transcription factors, including
PU.1, influence cell fate decisions (4, 27). The multiple lin-
eages and developmental stages of hematopoietic cells and
the rarity of the multipotent progenitors have made testing
this model using endogenous expression levels in primary
cells problematic. Therefore, most studies have focused on
model cell lines and/or overexpression systems. To study the
function of PU.1 in adult hematopoietic cell development,
we generated a PU.1gfp reporter allele that has allowed us to
determine accurately the levels of PU.1 expression in all he-
matopoietic cell types and their early progenitors.
The analysis of GFP expression by mature hematopoietic
cells of adult PU.1gfp/gfp mice confirmed the previous findings
that monocytes/granulocytes expressed significantly higher
levels of PU.1 (approximately eightfold) as compared with B
cells (14, 17). The strikingly uniform expression of PU.1 in
both lineages, the relatively similar protein stability between
GFP and PU.1, and the exquisite sensitivity of the fluores-
cence (heterozygous cells contained exactly 50% GFP levels
of homozygous cells) demonstrated that the reporter would
enable the quantitative analysis of the mean GFP fluores-
cence in defined cell populations. A broader analysis revealed
that PU.1 is silenced at an earlier stage in erythrocytes, NK
cells, and T cells. Within the DC lineages, PU.1 showed
specific expression levels, with the cDC populations having
uniformly high levels of PU.1 comparable to that of myeloid
cells, whereas the pDCs expressed moderate levels of PU.1
similar to that of B cells. cDC ontogeny is complex with at
least three distinct subsets, CD8 , CD4 , and double nega-
tive, which are derived from both lymphoid and myeloid
progenitors (for review see reference 28). However, GFP
expression was uniform within all cDCs, suggesting that
PU.1 levels are not related to the phenotype or origins of the
lineage. The similar levels of GFP in pDCs compared with B
Table II. Generation of myeloid cells and DCs in vivo by CMP subpopulations
CMP subpopulations Donor-derived cells ( 104)
Injected ( 104) Mac-1  Gr-1  cells in BMa Mac-1  Gr-1  cells per spleen CD11c  DCs per spleen
Flt3  PU.1hi 3.1–16.0 52.0–78.1 26.5–59.2
Flt3  PU.1hi 7.9–8.5 34.4–52.9 3.1–8.5
Flt3  PU.1lo 0.4–0.6 2.9–15.9 0.1–0.5
Purified BM progenitor populations from PU.1gfp/gfp mice (C57BL/6 Ly5.2) were intravenously injected into lethally irradiated Ly5.1 recipient mice. For myeloid cell generation, the 
recipient mice were analyzed 10 d after injection. For DC generation, recipient mice were analyzed 14 d after injection. The values in this table are the ranges of donor-derived 
cell numbers obtained from two experiments. Each experiment included two to three recipients for each precursor population.
aDonor-derived cells in the BM of two femur and two tibia collected from each mouse.REGULATION OF PU.1 LEVELS DURING HEMATOPOIESIS | Nutt et al. 228
cells may reflect the shared genetic program between these
cell types, regardless of lymphoid or myeloid origin, result-
ing in D-JH recombinations at the IgH locus (29) and the
expression of common transcriptional regulators, including
Spi-B (30, 31).
The analysis of expression of PU.1 in multipotent BM
progenitors has to date been restricted to RT-PCR (2, 26,
32). These approaches have suggested that PU.1 is expressed
in all progenitor fractions but are problematic due to the dif-
ficulties inherent in controlling for sorting purity, generating
cDNA from these rare cells, and the interpretation of the
data due to the reported promiscuous low level transcrip-
tional priming of noncommitted progenitor cells (32). For
example, the original description of PU.1 expression in de-
fined erythro-myeloid progenitors suggested equally low ex-
pression in all populations (2), whereas a subsequent study
has suggested that PU.1 mRNA levels are higher in GMPs
than MEPs (26). The heterogeneity of the CMP reported
here makes such a population level analysis uninformative.
In contrast, the PU.1gfp reporter mice enabled us to quantify
the levels of PU.1 expression at a single cell level. Overex-
pression studies have shown that the lineage fate of PU.1 / 
fetal liver progenitors can be directed by the ectopically ex-
pressed PU.1(14–16). These experiments have led to the
prediction that PU.1 will be lowly expressed in most primi-
tive progenitors, up-regulated in the CMP, and remain low
in the CLP (15). Our results suggest an alternate model as we
found that PU.1 was already expressed at high levels in the
HSC. Moreover, we found that the CLP and CMP were
comparably GFP fluorescent, suggesting that the PU.1 level
was not the determining factor of lympho-myeloid lineage
commitment. In contrast, the high level PU.1 expression in
this early progenitor stage and undetectable CLPs and CMPs
in the BM of mice with induced deletion of PU.1 (unpub-
lished data) support a requirement for PU.1 in the transition
of HSCs to the CLP or CMP stages of adult hematopoiesis.
Within the lymphoid lineages, the earliest progenitor, the
CLP, expressed high levels of PU.1, which was down-regu-
lated during the transition from CLPs to committed T or B
cells. All B cells expressed low levels of PU.1, whereas PU.1 is
silenced at the TN3 stage of T lymphopoiesis, a finding con-
sistent with previous RT-PCR studies (24). This down-regu-
lation is required for progression in the T cell lineage because
enforced constitutive expression of PU.1 during T cell devel-
opment results in growth inhibition and an arrest at the pro–T
cell (TN2) stage (24). These findings suggest that the high
PU.1 expression in the CLP is repressed upon B/T cell com-
mitment to the characteristic low B cell expression state and
completely repressed to allow T cell development.
In contrast to the uniform expression of PU.1gfp in the
HSC and CLP, we found clear evidence of heterogeneity in
the CMP. The CMPs were originally reported as clonogenic
myeloid precursors (2). However, recent studies of ours (20)
and others (33) demonstrated that the CMP could be di-
vided into two fractions based on the Flt3 expression. The
Flt3  CMPs were shown to be more efficient progenitors for
myeloid cells and DC populations than the Flt3  CMPs (20,
33). The Flt3  CMPs also contain precursors of B cells (20).
In this study, we showed that the different levels of PU.1 ex-
pression further subdivided the Flt3  CMP into two popula-
tions, namely the Flt3  PU.1hi and the Flt3  PU.1lo CMPs.
These populations were morphologically very similar but in
vitro colony formation and the in vivo precursor transfer as-
says demonstrated the differences in progenitor potentials of
these three CMP populations, with the Flt3  PU.1hi cells as
the most efficient progenitors for myeloid cells and DCs, the
Flt3  PU.1hi cells as efficient progenitors for myeloid cells
but not for DCs, and the Flt3  PU.1lo cells as containing
progenitors mainly for MegE. CMPs have been demon-
strated to be direct precursors of the GMP and MEP popula-
tions (2). Here we have shown that the Flt3  PU.1hi and
Flt3  PU.1hi CMPs directly differentiated into GMP-like
cells, whereas the Flt3  PU.1lo cells differentiated to MEPs.
The lack of true bipotent cells in these fractions in this assay
suggests that the true CMP is either a relatively small pro-
portion of the defined gate or confined to an as yet unidenti-
fied earlier stage. In summary, we have demonstrated that
the CMP contains at least three phenotypically, functionally,
and developmentally distinct cell subsets.
The fact that the Flt3  PU.1lo cells were highly enriched
for clonogenic MegE progenitors together with the very low
levels of PU.1 expression by the MEP and the induction of
the MegE regulator gata-1 by these cells suggests that down-
regulation of PU.1 is one of the first events associated with
the restriction to MegE differentiation. Although it is at
present not definitively known whether this down-regula-
tion is essential for erythroid commitment, studies using viral
integration or transgenic overexpression demonstrate that
PU.1 is incompatible with normal erythropoiesis as ectopic
PU.1 blocks early erythroid differentiation, resulting in eryth-
roleukemia (22, 34). In contrast, forced gata-1 expression in
vivo reprograms CLP and GMP to the MegE lineages (26).
It has been proposed that the interactions of these proteins
are direct and result in functional antagonism of either part-
ner (35–38). These results emphasize the importance of con-
sidering the functionality of PU.1 as well as its expression
level. PU.1 can be serine phosphorylated and interacts with
a variety of other transcription factors (8). Although the
PU.1gfp model does not allow us to discern such posttransla-
tion influences, the transcriptional down-regulation or PU.1
in the Flt3  PU.1lo CMP and MegE lineages allows us
to propose that the primary determinant of PU.1 versus
GATA-1 stoichiometry and lineage determination occurs via
transcriptional regulation as few or no progenitors coexpress
high levels of both transcripts.
The genetic elements underlying this dynamic expression
pattern of PU.1 have not been determined. Deletion of a dis-
tal enhancer  14-kb upstream of the start of transcription
was recently shown to reduce expression to 20% that of wild-
type cells (9). However, that study did not ascertain if the re-JEM VOL. 201, January 17, 2005 229
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duction in PU.1 was uniform or lineage/differentiation-stage
specific. Interestingly, these mice developed AML with a
high frequency, indicating that the regulation of PU.1 ex-
pression is an essential process in controlling hematopoietic
malignancies. PU.1 has also been proposed to autoregulate its
own transcription with PU.1 /  fetal liver cells lacking the
truncated  PU.1 mRNA (5, 39). Therefore, antagonizing
PU.1 function would break this autoregulatory loop and pro-
vide a simple method to reduce expression. The PU.1gfp mice
will provide an excellent tool to address this question.
This study has revealed a complex and dynamic expres-
sion pattern of PU.1 throughout adult hematopoiesis. We
propose that PU.1 transcription is controlled at multiple
points in hematopoiesis. PU.1 is induced in the most primi-
tive HSC and maintained at this high level in lymphoid and
myeloid progenitors. In contrast, PU.1 down-regulation is
an early event in the loss of myeloid differentiation capacity
associated with commitment to megakaryo-erythropoiesis.
Upon unilineage commitment, PU.1 expression is further
modified to result in the characteristic high levels in macro-
phages, low levels in B cells, and transcriptional silencing in a
number of other cell types.
MATERIALS AND METHODS
Generation of PU.1gfp mice. The pKW11 vector consists of a splice ac-
ceptor, stop codons in all reading frames, an IRES, eGFP cDNA, and a
SV40 polyadenylation signal, and a PGK-Neor gene was introduced into the
3  untranslated region of PU.1 by homologous recombination in C57BL/6
ES cells. Targeted ES cell clones were injected into BALB/c blastocysts to
obtain chimeric founders. Germline transmission was achieved with two
clones that gave identical patterns and levels of GFP fluorescence. Mice
were bred and maintained at the Walter and Eliza Hall Institute under ani-
mal ethics guidelines.
Antibodies. The following mAbs were used as supernatants for immuno-
magnetic bead depletion of lineage marker  BM cells: CD3 (KT-3.1), CD8
(53–6.7), CD2 (RM2-1), B220 (RA3-6B2), Mac-1 (M1/70), Gr-1 (RA6-
8C5), and Ter-119. The following supernatants were used for depletion in
splenic DC and pDC preparations: CD3, CD19 (ID3), CD90 (T24/31.7),
Gr-1, and Ter-119. For thymic DC and pDC preparation, CD11b (M1/70)
and F4/80 were also added to the depletions. Note that the use of Gr-1 did
not cause depletion of pDCs (40).
The following mAbs were used for cell staining and sorting: Gr-1,
CD19, Ter-119, CD49b (HM 2), CD8, CD45RA (14.8), and Flt3
(A2F10.1) used as a PE conjugate; c-kit (CD117) (2B8), Thy1.2 (30H12),
and NK1.1 (PK136) used as an allophycocyanin (APC) conjugate; Sca-1
(E13-161-7), CD4, CD11c (N418), and IL–7R  (A7R34) used as Alexa
594 conjugates; and Ly 5.2 (AL1-4A2), Fc RII/III (CD16/32(2.4G2)), IL-
7R   (A7R34), CD25 (PC61), B220, Mac-1, CD71 (C2), CD43 (S7),
CD122 (Tm- 1), and CD34 (RAM34) were biotinylated. mAbs were pu-
rified from hybridoma supernatants with the exception of CD71, CD43,
CD122, c-kit, and CD34, which were from BD Biosciences. Anti–rat im-
munoglobulin–Texas red, PE-avidin, or PerCp–Cy5.5-avidin (all from BD
Biosciences) were used for second-stage staining.
Isolation of BM precursor populations. The early intrathymic lym-
phoid precursors (41) and BM precursor populations (42) were purified as
described previously. In brief, HSC and CLP populations from BM were
purified by immunomagnetic bead depletion of lineage marker  cells, fol-
lowed by staining with c-kit–APC, Sca-1–Alexa 594, and IL-7R –biotin,
followed by PE-avidin. The HSC was identified as Lin  IL-7R   Sca-1hi
c-kithi. The CLP was identified as Lin  IL-7R   Sca-1int c-kitint cells. The my-
eloid precursor populations from BM were isolated by first depleting lineage
marker  cells by means of immunomagnetic beads. The remaining cells were
then stained with goat anti–rat immunoglobulin–Texas red, Sca-1–Alexa
594, IL-7R –Alexa 594, c-kit–APC, Flt3-PE, FcR II/III (CD16/32)–bio-
tin, and followed by PerCP–Cy5.5-avidin. The previously described CMP
population was identified as Lin  Sca-1  IL-7R   c-kit  CD16/32low cells.
The CMPs can be further divided into three populations based on Flt3 and
PU.1gfp expression, namely Flt3  PU.1hi, Flt3  PU.1hi, and Flt3  PU.1lo. Be-
cause of limitations in the available fluorescent channels, our gating for the
CMP populations differed from that previously published in that it did not
include CD34 (2). We believe that the parameters used in this study identify
the same CMP population as those defined previously (for details see Fig.
S1, available at http://www.jem.org/cgi/content/full/jem.20041535/DC1).
The GMP was identified as Lin  Sca-1  IL-7R   c-kit  CD16/32  CD34 
cells and the MEP was Lin  Sca-1  IL-7R   c-kit  CD16/32  CD34 . The
stained cells were analyzed or sorted using a FACStarPLUS or a DiVa instru-
ment (BD Biosciences). The BM pre-pro–B cells were purified by immuno-
magnetic bead depletion of lineage marker  (except B220 ) cells, and then
stained with CD19-PE, B220-Cy5, and CD43-biotin (revealed with Alexa
594 avidin). Pre-pro–B cells were defined as CD19  B220  CD43 . The
purity of sorted cells was determined by reanalyzing a small sample of the
collected cells and was usually  97%. Fractionated BM progenitors were cy-
tocentrifuged onto slides and stained with May-Grunwald-Giemsa solution.
Determination of PU.1gfp expression. The PU.1gfp expression by differ-
ent hematopoietic cell populations was examined by flow cytometric analysis.
The level of PU.1gfp was determined by the relative mean fluorescence, i.e.,
the mean fluorescence of a defined cell population of PU.1gfp/  or PU.1gfp/gfp
mice subtracted with the mean fluorescence of the same cell population of the
control C57Bl/6 mice. As the fluorescence intensity of equivalent cell popu-
lations varied between the analytical flow cytometer (Fig. 1, LSR; BD Bio-
sciences) and the DiVa instrument (Figs. 2–4; BD Biosciences), only relative
fluorescence in arbitrary units is indicated for each histogram.
Western blotting. Total protein extracts were produced from equivalent
numbers of cells and Western blotting was performed as described previ-
ously (43). Rabbit anti-PU.1 (T21), rabbit anti-GFP (FL), and goat anti– 
actin (I-19) were from Santa Cruz Biotechnology, Inc. Specific protein sig-
nals were determined by densitometry of the resulting X-ray film.
In vitro cell culture. For the analysis of protein stability, erythrocyte-
depleted splenocytes were cultured in IMDM and 10% FCS with 50  g/ml
cyclohexamide added at appropriate time points before the completion of
the 12-h culture. Sorted progenitor cell populations were seeded at 10,000
cells/100  l in IMDM, 10% FCS, and 100  g/ml SCF on a semiconfluent
layer of S17 stroma as described previously (2). Cells were analyzed after
40 h. CD49b  TCR   NK cells were FACS sorted from the spleen and
cultured in 50 ng/ml IL-15 for 7 d as described previously (44).
In vivo hematopoietic cell lineage reconstitution. The CMP popula-
tions were purified from the BM of PU.1gfp/gfp (C57BL/6 Ly5.2) mice and
then intravenously injected together with 5   104 recipient-type BM cells
into lethally irradiated (550 rads, twice) C57BL/6 Ly5.1 recipient mice. 10 d
after injection, the donor-derived cells in the recipient thymus, spleen, and
BM were analyzed by flow cytometry. Donor-derived myeloid cells were
identified as Ly5.2  Mac-1  or Gr-1 . The donor-derived B and T cells were
identified as Ly5.2  CD19  B220  and Ly5.2  CD4  or CD8 , respectively.
For DC production, the recipient mice were analyzed 14 d after precursor
transfer. The splenic DCs were prepared and stained as described elsewhere
(45), and the donor-derived DCs were identified as Ly5.2  CD11c .
Semisolid culture of BM progenitors. BM cells were cultured in 0.3%
agar cultures and analyzed as described previously (46). The recombinantREGULATION OF PU.1 LEVELS DURING HEMATOPOIESIS | Nutt et al. 230
cytokines were used at the following concentrations: 10 ng/ml IL-3, 100
ng/ml SCF, and 2 IU/ml erythropoietin. Differential colony counts were
performed on fixed preparations stained for acetylcholinesterase, Luxol fast
blue, and hematoxylin.
RT-PCR analysis. Semiquantitative RT-PCR was performed as de-
scribed previously (47). cDNA concentrations were normalized to hprt by
dilution analysis. PU.1 primers were as follows: PU1 number 1: GTTTT-
CCCTCACCGCCCCTCCAT; PU1 number 2: CTGCCTCTCACCC-
TCCTCCTCATC. All other primer sets have been described (48).
cDNA. Amplification products all spanned introns and were visualized on
2% agarose gels.
Online Supplemental Material. Fig. S1 shows the parameters used for
the sorting and analysis of PU.1gfp expression by BM progenitor populations
and compares CMP populations defined in this and previous studies. Fig. S1
is available at http://www.jem.org/cgi/content/full/jem.20041535/DC1.
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